{"entity":{"id":"nct06448572","kind":"trial","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","aka":["EXLIBRIS"],"tldr":"A phase 1/2 trial in lung cancer, run by University Hospital, Lille, now recruiting.","summary":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. is a phase 1/2, interventional study registered as NCT06448572 by University Hospital, Lille, with a registry enrolment figure of 21 participants, started 2024-07-16 and due to reach its primary completion in 2028-10-01. Interventions recorded: EXL01. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-free survival rate (PFS Rate) for the assessment of efficacy, defined as the rate of alive and non-progressive subjects as per iRECIST 1.1 over the study subjects.. Lung eligibility wording from the registry: \"Histologically or cytologically documented inoperable advanced/metastatic NSCLC\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06448572","url":"https://clinicaltrials.gov/study/NCT06448572"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06448572","phase":"1/2","setting":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy","sponsor":"University Hospital, Lille","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06448572/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}